Can enasidenib really cure the disease?

Real-world data indicate that patients with relapsed or refractory acute myeloid leukemia (AML) have poor prognosis; therefore, improved new therapies are critical in these settings. Previous data also showed that up to one in five patients may have the disease with an IDH2 mutation. Ensidipine (Enasidenib) is a selective inhibitor of 2-HG production, which is dysregulated in patients with IDH2 mutations. The drug was approved by the U.S. Food and Drug Administration for the treatment of relapsed/refractory AML in the context of IDH2 mutations.

Ensidipine is a widely studied and used drug that can have a positive impact on a patient's condition in certain situations. However, treatment results vary from individual to individual and require physician evaluation and guidance based on the patient's specific circumstances. In individual patients, ensidipine may show therapeutic benefit. However, different patients may have different conditions and therefore the effectiveness of treatment will also vary. It is important to have a detailed discussion with your doctor about individualized treatment options and expected effects and side effects.

Ensiidi plain investigational medicine is not currently on the market in the country, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.